Edition:
United States

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

43.14USD
13 Aug 2018
Change (% chg)

$-0.50 (-1.15%)
Prev Close
$43.64
Open
$43.54
Day's High
$44.12
Day's Low
$42.63
Volume
226,065
Avg. Vol
340,705
52-wk High
$52.95
52-wk Low
$14.57

Latest Key Developments (Source: Significant Developments)

Ptc Therapeutics To Acquire Agilis Biotherapeutics
Thursday, 19 Jul 2018 04:10pm EDT 

July 19 (Reuters) - PTC Therapeutics Inc ::PTC THERAPEUTICS TO ACQUIRE AGILIS BIOTHERAPEUTICS.PTC THERAPEUTICS INC - TRANSACTION WAS APPROVED BY BOARDS OF BOTH COMPANIES.PTC THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, PTC TO PAY UPFRONT CONSIDERATION OF $50 MILLION IN CASH AND APPROXIMATELY $150 MILLION IN PTC COMMON STOCK.PTC THERAPEUTICS INC - ADDITIONALLY, TRANSACTION INCLUDES UP TO $535 MILLION IN SUCCESS-BASED MILESTONES.PTC THERAPEUTICS INC - BLA SUBMISSION IN AADC DEFICIENCY EXPECTED IN 2019.PTC THERAPEUTICS - IN ADDITION TO UPFRONT PAYMENTS, POTENTIAL FUTURE PAYMENTS INCLUDES $60 MILLION IN DEVELOPMENT MILESTONES TO BE PAID OVER NEXT 2 YRS.PTC THERAPEUTICS INC - AN IND SUBMISSION FOR GENE THERAPY ASSET TARGETING FRIEDREICH ATAXIA PROGRAM IS EXPECTED IN 2019.PTC THERAPEUTICS INC - DEAL ALSO INCLUDES RECEIPT OF PRIORITY REVIEW VOUCHER, $150 MILLION TIERED COMMERCIAL MILESTONES, AMONG OTHERS.  Full Article

PTC Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 27 Mar 2018 04:04pm EDT 

March 27 (Reuters) - Ptc Therapeutics Inc ::PTC THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.PTC THERAPEUTICS INC - COMMENCING A PUBLIC OFFERING OF 4 MILLION SHARES OF ITS COMMON STOCK.  Full Article

Ptc Therapeutics Says ‍Firefish Study Of RG7916 In Type 1 Spinal Muscular Atrophy Patients Transitioned Into Pivotal Phase With Dosing First Patient​
Thursday, 15 Mar 2018 08:00am EDT 

March 15 (Reuters) - Ptc Therapeutics Inc ::PTC THERAPEUTICS INC - ‍FIREFISH STUDY OF RG7916 IN TYPE 1 SPINAL MUSCULAR ATROPHY PATIENTS TRANSITIONED INTO PIVOTAL PHASE WITH DOSING FIRST PATIENT​.  Full Article

PTC Therapeutics Q4 Revenue $78.0 Million
Tuesday, 6 Mar 2018 04:01pm EST 

March 6 (Reuters) - PTC Therapeutics Inc ::‍TOTAL REVENUES FOR Q4 OF 2017 WERE $78.0 MILLION COMPARED TO $25.2 MILLION IN Q4 OF 2016​.SEES ‍FULL YEAR 2018 NET PRODUCT REVENUES TO BE BETWEEN $260 AND $295 MILLION​.‍PTC ANTICIPATES TRANSLARNA NET PRODUCT REVENUE FOR FULL YEAR 2018 TO BE BETWEEN $170 AND $185 MILLION​.‍PTC PROJECTS A 5-YEAR (DECEMBER 31, 2022) COMPOUND ANNUAL GROWTH RATE OF 15% FOR NET PRODUCT REVENUES​.‍PTC ANTICIPATES EMFLAZA NET PRODUCT REVENUE FOR FULL YEAR 2018 TO BE BETWEEN $90 AND $110 MILLION​.QTRLY ‍SHR $ 0.03​.Q4 REVENUE VIEW $74.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

PTC Therapeutics Receives Formal Dispute Resolution Request Decision
Tuesday, 20 Feb 2018 08:00am EST 

Feb 20 (Reuters) - PTC Therapeutics Inc ::PTC THERAPEUTICS RECEIVES FORMAL DISPUTE RESOLUTION REQUEST DECISION FROM THE FDA'S OFFICE OF NEW DRUGS.PTC THERAPEUTICS INC - OFFICE OF NEW DRUGS OF U.S. FDA DENIED PTC'S APPEAL OF COMPLETE RESPONSE LETTER IN RELATION TO NDA FOR ATALUREN.PTC THERAPEUTICS INC - OFFICE OF NEW DRUGS RECOMMENDED A POSSIBLE PATH FORWARD FOR ATALUREN NDA SUBMISSION BASED ON ACCELERATED APPROVAL PATHWAY.PTC THERAPEUTICS- LETTER FROM OFFICE OF NEW DRUGS ADDS CO'S STUDY 041 COULD SERVE AS CONFIRMATORY POST-APPROVAL TRIAL NEEDED FOR ACCELERATED APPROVAL.PTC THERAPEUTICS INC - PTC CURRENTLY INTENDS TO MAINTAIN PATIENTS IN U.S. CURRENTLY RECEIVING ATALUREN FOR NMDMD.  Full Article

PTC Therapeutics reports qtrly net loss per share basic and diluted of $0.82
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Ptc Therapeutics Inc ::Qtrly total revenues $41.9 million versus $22.98 million.Qtrly net loss per share basic and diluted $0.82.Q3 earnings per share view $-0.68, revenue view $42.2 million -- Thomson Reuters I/B/E/S.Increasing 2017 revenue guidance to $160-$185M​.FY2017 revenue view $173.4 million -- Thomson Reuters I/B/E/S.  Full Article

PTC THERAPEUTICS ANNOUNCES DATA FROM PART 1 OF SUNFISH TRIAL
Tuesday, 3 Oct 2017 10:12am EDT 

Oct 3 (Reuters) - PTC Therapeutics Inc ::RG7916 INCREASED SMN PROTEIN PRODUCTION IN SUNFISH CLINICAL TRIAL IN PATIENTS WITH TYPE 2/3 SPINAL MUSCULAR ATROPHY.PTC THERAPEUTICS INC - RG7916 REMAINS WELL-TOLERATED IN PATIENTS AT ALL DOSES AND THERE HAVE BEEN NO DRUG-RELATED SAFETY FINDINGS LEADING TO WITHDRAWAL​.PTC THERAPEUTICS INC SAYS ANNOUNCED DATA FROM PART 1 OF SUNFISH TRIAL OF RG7916 IN TYPE 2/3 SPINAL MUSCULAR ATROPHY PATIENTS​.  Full Article

PTC Therapeutics files for potential mixed shelf; size not disclosed - SEC filing‍​
Thursday, 24 Aug 2017 06:07pm EDT 

Aug 24 (Reuters) - Ptc Therapeutics Inc :Files for potential mixed shelf; size not disclosed - SEC filing‍​.  Full Article

PTC Therapeutics qtrly loss per share $0.44
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Ptc Therapeutics Inc :Ptc therapeutics - qtrly total revenues $48 million versus $15.6 million; qtrly loss per share $0.44; sees fy translarna net sales $120 million - $140 million ‍​.Q2 earnings per share view $-1.28, revenue view $28.8 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $142.2 million -- Thomson Reuters I/B/E/S.  Full Article

Great Point Partners Llc reports 5.24 percent passive stake in PTC Therapeutics Inc
Friday, 16 Jun 2017 04:09pm EDT 

June 16 (Reuters) - Great Point Partners lLC::Great Point Partners LLC reports 5.24 percent passive stake in PTC Therapeutics Inc <<>> as of June 6, 2017 .  Full Article

BUZZ-PTC Therapeutics: Jumps on deal to buy Agilis Biotherapeutics

** Drug developer's shares up nearly 9 pct at $40.07 in early trading on Friday